Citizens analyst Jonathan Wolleben has maintained a Market Outperform rating on DBV Technologies and raised the price target to $55 from $47. The adjustment reflects a revised outlook on the company's stock performance.

Rating and Price Action

The analyst's decision to upgrade the price target comes as DBV Technologies continues to navigate its market position. The previous target of $47 has been lifted to $55, indicating confidence in the stock's potential upside.

Key Details

The rating reaffirms the analyst's positive stance on DBV Technologies, which trades on the NASDAQ under the ticker DBVT.

DBV Technologies, a late-stage biopharmaceutical company, is preparing to submit a Biologics License Application (BLA) for the VIASKIN Peanut Patch in children aged four through seven years in the third quarter of 2026. The company has engaged in detailed discussions with the U.S. Food and Drug Administration (FDA) to optimize the review process, receiving feedback on the organization and formatting of existing data sets for the CMC and biostatistical elements of the application. The FDA has not requested additional data, allowing the company to proceed with filing after incorporating the agency's input.

Daniel Tassé, Chief Executive Officer of DBV Technologies, stated that the VIASKIN Peanut Patch is a novel product with no regulatory precedent. He noted that the recent dialogue with the FDA has been productive, allowing the company to enhance its BLA submission prior to filing. Tassé expressed gratitude for the agency's collaboration and constructive engagement during this preparatory phase.

Key Details of the BLA Update

DBV Technologies is focused on developing treatment options for food allergies and other immunologic conditions using its proprietary VIASKIN Patch technology. The company's programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut-allergic toddlers and children. DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ.